

Canine saliva is a source of interspecies antimicrobial resistance gene transfer

Adrienn Gréta Tóth¹, Imre Tóth^{2,3}, Bernadett Rózsa⁴, Eszter Gabriella Kovács¹, Attila Dubecz⁵, Árpád V. Patai^{6,7}, Tibor Németh⁸, Selçuk Kaplan⁹, László Makrai¹⁰, and Norbert Solymosi^{1,11*}

¹Centre for Bioinformatics, University of Veterinary Medicine Budapest, 1078 Budapest, Hungary

²Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary

³Department of Thoracic Surgery, Borsod-Abaúj-Zemplén County Hospital, and University Teaching Hospital, 3526 Miskolc, Hungary

⁴Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL 36088, USA

⁵Department of Surgery, Paracelsus Medical University, 90419 Nuremberg, Germany

⁶Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary

⁷Interdisciplinary Gastroenterology Working Group, Semmelweis University, Budapest, Hungary

⁸Department and Clinic of Surgery and Ophthalmology, University of Veterinary Medicine Budapest, 1078 Budapest, Hungary

⁹Tekirdag Namik Kemal University, Faculty of Veterinary Medicine, Department of Genetics, 59100 Tekirdag, Turkey

¹⁰Department of Microbiology and Infectious Diseases, University of Veterinary Medicine Budapest, Budapest, 1143 Hungary

¹¹Eötvös Loránd University, Department of Physics of Complex Systems, 1117 Budapest, Hungary

*solymosi.norbert@gmail.com

ABSTRACT

While the One Health issues of intensive animal farming are commonly discussed, keeping companion animals is less associated with the interspecies headway of antimicrobial resistance. With the constant advance of veterinary standards, antibiotics are regularly applied in companion animal medicine. Due to the close coexistence of dogs and humans, dog bites and other casual encounters with dog saliva (e.g. licking the owner) are common. According to our metagenome studies based on 47 new generation sequencing canine saliva datasets from 2020 and 2021 deposited in NCBI SRA by The 10,000 Dog Genome Consortium and the Broad Institute, canine saliva is rich in bacteria with predictably transferable antimicrobial resistance genes (ARGs). In the genome of potentially pathogenic *Bacteroides*, *Capnocytophaga*, *Corynebacterium*, *Fusobacterium*, *Pasteurella*, *Porphyromonas*, *Staphylococcus* and *Streptococcus* species, that are some of the most relevant bacteria in dog bite infections, ARGs against aminoglycosides, carbapenems, cephalosporins, enrofloxacin, glycolcyclines, lincosamides, macrolides, oxazolidinone, penams, phenicols, pleuromutilins, streptogramins, sulfonamides and tetracyclines could be identified. Several ARGs, including ones against amoxicillin-clavulanate, the most commonly applied antibiotic by dog bites, was predicted to be potentially transferable based on their association with mobile genetic elements (e.g. plasmids, phages, integrated mobile genetic elements). According to our findings canine saliva may be a source of transfer of ARG-rich bacteria, that can either colonize the human body or transport ARGs to the host bacteriome and thus can be considered as a risk in the spread of antimicrobial resistance.

Background

Antimicrobial resistance is a threat of utmost significance that constantly raises medical challenges all around the globe. The fact that main drivers of the headway of antimicrobial resistance (AMR) are antimicrobial use and abuse is well-accepted. Moreover, according to the concept of One Health, the effects of antimicrobial use in human, animal and environmental sectors are interconnected, and thus interdependent. In case of AMR, the relatedness of human and animal dimensions described by the One Health approach can be the best referred by considering that most antimicrobial classes are co-used in both sectors. Human health antimicrobial use has been overshadowed for years by farm animal mass medication, although this tendency has recently changed at some parts of the world¹. While the appearance and advance of AMR, and as an underlying cause, the enrichment and transmission of antimicrobial resistance genes (ARGs) in antibiotic-dense environments, such as intensive

animal production farms is a well-examined phenomenon^{2,3}, the spread of AMR may also derive from other animal-borne routes.

Over the past decades, the number of companion animals has been tendentially and steadily rising⁴. Between 2000 and 2017 the number of dogs in the United States escalated from 68 million to 89.7 million⁵. 67.9% of all households in the U.S. was associated with the ownership of various pet species and 48% of all with dogs in 2016⁴. In years 2019-2020 50% of U.S. population owned a dog⁶. Coronavirus Disease (COVID-19) Pandemic outbreak has resulted in elevated companion animal acquisition rates, albeit often followed by retention or replacement^{7,8}. Besides the popularity of keeping small animals, the quality of human-pet bond has also changed. According to the survey of the American Veterinary Medical Association, 70% of pet owners consider their pets as family members, 17% as companions and 3% as property⁹. The role of pets can principally be defined as social companionship. Nowadays having physical proximity is very common by pet-owner coexistences, pets often sleep together with their owners and lick their face or wounds¹⁰. Unfortunately and unsurprisingly, with such high dog numbers, the occurrence of dog bites is also common. Between 2001 and 2003, approximately 4.5 million dog bites were registered yearly in the United States, 19% of which necessitated medical intervention¹¹. In years 2005-2013 an average of 337,103 dog bite injuries were treated at the U.S. emergency departments¹², although dog bites in general are under-reported¹³. Interestingly, 3 of 5 bites are executed by family dogs, what is more common than attacks by strays¹⁴. According to some statistics, some dog breeds including pit bulls, rottweilers and German shepherds are more likely to commit attacks, although any dog breeds may bite¹⁵. According to the current ranking of the American Kennel Club, German shepherds are the 3rd and rottweilers are the 8th most popular dog breeds, while pit bulls are banned in many states.

According to a publication from 2017, dogs make up 64.8% of the veterinary-visiting population in Great Britain¹⁶. Another study executed on a representative number of U.S. residents suggests that approximately 90% of cat and dog owners had taken a visit at a veterinarian at any time and about 40% visited a veterinarian annually¹⁷.

The modern mindset of providing regular veterinary healthcare services to our pets and keeping them in our closest surroundings may contribute to the interspecies transmission of AMR. Several studies have already turned the attention to the role of companion animals in the headway of AMR¹⁸⁻²². Nevertheless, the significance of the direct pet-borne AMR spread route has been given less attention when compared with the rather indirect, mostly food-transmitted farm animal associated route. The routes of ARG transmission can be assessed by analyzing the genetic surroundings of ARGs. Genetic elements that facilitate horizontal gene transfer (HGT) including plasmids, bacteriophages and integrative mobile genetic elements (iMGEs) may contribute to three different HGT processes, namely conjugation, transduction or transformation. By conjugation, genes are delivered to a recipient cell on plasmids if bacterial cells are physically binded, while by transduction, direct cell-to-cell contact is disclaimed due to the presence of bacteriophages, as means of gene conduit. Transformation negates the need for particular delivery processes. In this case, bacteria take up genetic fragments from their environment²³. After dog bites or close encounters with saliva from dogs that undergo veterinary treatments and thus carry bacteria with an enriched ARG content, resistant bacteria may be introduced to the human body and later the HGT of antimicrobial resistance determinants may be exchanged with the host bacteriota. Our study aimed to reveal the ARG content of 47 canine saliva samples from the U.S., attach the ARGs with the bacterial species that they derive from and report the ARGs' spreading capabilities to weigh the above-mentioned phenomenon. For this purpose, freely accessible next-generation sequencing (NGS) shotgun datasets were downloaded and bioinformatically analyzed using an advanced metagenomic pipeline.

Materials and Methods

We searched deep sequenced canine saliva datasets in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) repository. In May 2021, we found two shotgun metagenomic BioProjects (PRJNA648123⁷⁷, PRJNA683923) that had more than 100,000,000 paired-end reads per sample (Table 1). The median read count (interquartile range, IQR) of the samples was 177.7×10^6 (26.6×10^6) and 417.7×10^6 (90.1×10^6) in datasets PRJNA648123 and PRJNA683923, respectively.

Bioinformatic analysis

Quality based filtering and trimming of the raw short reads was performed by TrimGalore (v.0.6.6, <https://github.com/FelixKrueger/TrimGalore>), setting 20 as a quality threshold. Only reads longer than 50 bp were retained and taxonomically classified using Kraken2 (v2.1.1)²⁴ and a database created (24/03/2021) from the NCBI RefSeq complete archaeal, bacterial, viral and plant genomes. For this taxon assignment the `-confidence 0.5` parameter was used to obtain more precise species level hits. The taxon classification data was managed in R²⁵ using functions of the packages phyloseq²⁶ and microbiome.²⁷ Reads were classified as origin of bacteria were assembled to contigs by MEGAHIT (v1.2.9)²⁸ using default settings. The contigs were also classified taxonomically by Kraken2 with the same database as above. From the contigs all possible open reading frames (ORFs) were gathered by Prodigal (v2.6.3)²⁹. The protein translated ORFs were aligned to the ARG sequences of the Comprehensive Antibiotic Resistance Database (CARD, v3.1.3)^{30,31} by Resistance Gene Identifier (RGI, v5.2.0) with Diamond³². The ORFs classified as perfect or strict were further filtered with 90% identity and 90% coverage.

Table 1. The list of analyzed samples obtained from National Center for Biotechnology Information Sequence Read Archive. Column Run contains the NCBI SRA run identifiers. Bacterial read count represents the number of the reads were classified taxonomically to any bacteria.

	BioProject	Run	Sex	Bacterial read count
1	PRJNA648123	SRR12330029	female	2,900,387
2		SRR12330041	female	16,153,172
3		SRR12330042	male	13,072,781
4		SRR12330043	male	13,774,332
5		SRR12330044	male	6,123,646
6		SRR12330045	female	16,707,766
7		SRR12330098	female	18,826,266
8		SRR12330104	male	27,598,592
9		SRR12330220	male	9,938,948
10		SRR12330260	female	17,642,933
11		SRR12330298	female	17,277,697
12		SRR12330356	male	13,988,719
13		SRR12330364	female	17,378,513
14		SRR12330377	male	12,155,726
15		SRR12330378	female	34,183,357
16		SRR12330382	female	22,353,314
17		SRR12330383	male	22,886,951
18		SRR12330384	male	18,328,656
19		SRR12330385	female	6,631,504
20	PRJNA683923	SRR13340511	female	254,700
21		SRR13340512	male	980,644
22		SRR13340513	male	505,088
23		SRR13340515	female	1,019,054
24		SRR13340516	female	0
25		SRR13340517	female	202,859
26		SRR13340518	female	74,663
27		SRR13340519	female	88,624
28		SRR13340520	male	650,331
29		SRR13340521	male	83,869
30		SRR13340522	female	189,322
31		SRR13340523	male	124,098
32		SRR13340524	female	339,780
33		SRR13340526	male	246,375
34		SRR13340527	female	201,492
35		SRR13340528	female	189,384
36		SRR13340529	male	143,511
37		SRR13340530	female	0
38		SRR13340531	female	0
39		SRR13340532	male	0
40		SRR13340533	male	0
41		SRR13340534	female	0
42		SRR13340535	female	6,752,169
43		SRR13340537	male	8,245,374
44		SRR13340538	male	41,212,470
45		SRR13340539	female	13,028,655
46		SRR13340540	female	6,964,460
47		SRR13340541	male	6,279,921

All nudged hits were excluded. The integrative mobile genetic element (iMGE) content of the ARG harbouring contigs was analyzed by MobileElementFinder (v1.0.3) and its database (v1.0.2).³³ Following the distance concept of Johansson et al.³³ for each bacterial species, only those with a distance threshold defined within iMGEs and ARGs were considered associated. In the MobileElementFinder database (v1.0.2) for *Bacteroides*, the longest composite transposon (cTn) was the *Tn6186*. In case of this genus, its length (8,505 bp) was taken as the cut-off value. For the genera *Enterococcus* and *Klebsiella* the *Tn6246* (5,147 bp) and *Tn125* (10,098 bp) provided the threshold, respectively. In the case of *E. coli*, this limit was the length of the *Tn1681* transposon, namely 24,488 bp, while for *P. aeruginosa* *Tn6060* (25,440 bp). As the database neither contains species-level, nor genus-level cTn data for the rest of the species, a general cut-off value was chosen for the contigs of these species. This value was declared as the median of the longest cTns per species in the database (10,098 bp).

The plasmid origin probability of the contigs was estimated by PlasFlow (v.1.1)³⁴ The phage content of the assembled contigs was predicted by VirSorter2 (v2.2.3)³⁵. The findings were filtered for dsDNAphages and ssDNAs. All data management procedures, analyses and plottings were performed in R environment (v4.1.0).²⁵

Results

After presenting the bacteriome and the identified AGRs (resistome), predictions regarding the mobility potential of ARGs were also resumed based on genetic characteristics that may play a significant role in HGT.

Bacteriome

By taxon classification, the number of reads aligning to bacterial genomes differed in the various samples. In the saliva median bacterial read count of the samples was 6.1×10^6 (IQR: 1.5×10^7).

The relative abundances of genera that achieved more than 1% of the bacterial hits in any of the saliva samples is shown in Figure 1. In the saliva samples the dominant genera (with mean prevalence) in descending order were *Porphyromonas* (49%), *Ralstonia* (46%), *Cutibacterium* (18%), *Prevotella* (15%), *Staphylococcus* (14%), *Methylobacterium* (11%), *Rahnella* (11%), *Pasteurella* (10%), *Capnocytophaga* (9%), *Neisseria* (9%), *Conchiformibius* (7%), *Frederiksenia* (7%), PRJNA648123⁷⁷ and PRJNA683923 *Actinomyces* (5%), *Campylobacter* (4%), *Desulfomicrobium* (4%), *Micrococcus* (4%), *Moraxella* (4%), *Rothia* (4%), *Acinetobacter* (3%), *Bacteroides* (3%), *Dermacoccus* (3%), *Fusobacterium* (3%), *Mycoplasmopsis* (3%), *Paracoccus* (3%), *Pseudomonas* (3%), *Treponema* (3%), *Bacillus* (2%), *Bradyrhizobium* (2%), *Brevibacterium* (2%), *Corynebacterium* (2%), *Kocuria* (2%), *Pantoea* (2%), *Serratia* (2%), *Streptococcus* (2%).




Figure 1. Saliva core bacteriome. The relative abundances of genera that achieved more than 1% of the bacterial hits in any of the samples. The dominant genera (with mean prevalence) in descending order were *Porphyromonas* (49%), *Ralstonia* (46%), *Cutibacterium* (18%), *Prevotella* (15%), *Staphylococcus* (14%), *Methylobacterium* (11%), *Rahnella* (11%), *Pasteurella* (10%), *Capnocytophaga* (9%), *Neisseria* (9%), *Conchiformibius* (7%), *Frederiksenia* (7%), *Actinomyces* (5%), *Campylobacter* (4%), *Desulfomicrobium* (4%), *Micrococcus* (4%), *Moraxella* (4%), *Rothia* (4%), *Acinetobacter* (3%), *Bacteroides* (3%), *Dermacoccus* (3%), *Fusobacterium* (3%), *Mycoplasmopsis* (3%), *Paracoccus* (3%), *Pseudomonas* (3%), *Treponema* (3%), *Bacillus* (2%), *Bradyrhizobium* (2%), *Brevibacterium* (2%), *Corynebacterium* (2%), *Kocuria* (2%), *Pantoea* (2%), *Serratia* (2%), *Streptococcus* (2%).

Resistome

The dominant mechanism of identified ARGs was the antibiotic inactivation (49.44%), antibiotic target protection (22.63%), antibiotic target alteration (15.36%), antibiotic efflux (7.54%), antibiotic target replacement (5.03%).




Figure 2. Identified antimicrobial resistance genes (ARGs) by samples. For each sample-ARG combination, only the best finding is plotted. The size and the colour of the dots correspond to the coverage and the sequence identity of hits on reference genes, respectively. In sample No. 20, 24-27, 29-31, 33-41 there was no identifiable ARG. The gene names that are too long have been abbreviated (*acrA*: *Escherichia coli* *acrA*; *emrE*: *E. coli* *emrE*; *KpnF*: *Klebsiella pneumoniae* *KpnF*).

The detected bacterial species were associated with the following ARGs: *Acinetobacter baumannii*: *aadA2*, *OXA-2*; *Actinobacillus pleuropneumoniae*: *ROB-1*; *Aeromonas hydrophila*: *ant(3'')-IIa*, *OXA-2*, *sulI*; *Alistipes indistinctus*: *tetQ*; *A. shahii*: *ermF*, *OXA-347*; *Amedibacterium intestinale*: *ant(6)-Ib*, *tet(44)*; *Bacteroides dorei*: *tetQ*; *B. fragilis*: *aadS*, *ermF*, *mef(En2)*, *OXA-347*, *tet(X5)*, *tetX*; *Bacteroides heparinolyticus*: *OXA-347*, *tetQ*; *B. ovatus*: *tetQ*; *Bacteroides* sp. HF-5287: *tetQ*; *Bibersteinia trehalosi*: *ROB-10*; *Blautia hansenii*: *tet32*; *Bulleidia* sp. zg-1006: *tet32*; *Capnocytophaga cynodegmi*: *cfxA2*; *Capnocytophaga* sp. H2931: *aadS*, *OXA-347*; *Capnocytophaga* sp. H4358: *aadS*, *OXA-347*; *C. stomatis*: *aadS*, *ermF*, *OXA-347*, *tet(X5)*; *Chryseobacterium indologenes*: *aadS*, *ermF*; *Chryseobacterium* sp. POL2: *OXA-347*; *Clostridioides*

difficile: aac(6')-PRJNA648123⁷⁷ and PRJNA683923Im, aph(2'')-IIa, ermG, tet32, tetM, tetO; *Clostridium cellulovorans*: tet32; *Conchiformibius steedae*: ROB-1; *Corynebacterium* sp. 1959: aph(3'')-Ib, aph(3')-Ia, aph(6)-Id, sul2; *Elizabethkingia anophelis*: OXA-347; *Empedobacter brevis*: OXA-347; *Enterocloster bolteae*: tetW; *E. faecalis*: tetM; *E. faecium*: aad(6), aph(3')-IIIa; *E. gilvus*: ermB; *E. hirae*: tetO; *Enterococcus* sp. FDAARGOS_375: ermB; *Escherichia coli*: acrA, aph(3')-Ia, aph(3')-IIa, emrE, emrK, gadW, gadX, mdtN, TEM-116, ugd; *Eubacterium maltosivorans*: tet32; *Eubacterium* sp. NSJ-61: tet32; *Faecalibacterium prausnitzii*: tet32, tetW; *Filifactor alocis*: tet(W/N/W); *Fusobacterium ulcerans*: OXA-85; *Geobacter daltonii*: ereA; *G. sulfurreducens*: OXA-119; *Glaesserella parasuis*: ROB-1, ROB-9; *Haemophilus haemolyticus*: ROB-1; *H. paraahaemolyticus*: aph(3'')-Ib, sul2; *Klebsiella michiganensis*: aph(3'')-Ib, aph(6)-Id, catIII, dfrA14, sul2; *K. quasipneumoniae*: aph(3')-Ia; *Lachnoanaerobaculum umeaense*: tet32; *Megasphaera stantonii*: tetW; *Mogibacterium pumilum*: tet(W/N/W), tetM; *Moraxella bovis*: aph(3'')-Ib, sul2; *Murdochiella vaginalis*: tetO; *Myroides odoratimimus*: OXA-347; *Neisseria animaloris*: aadA3; *N. shayegani*: aph(6)-Id; *Ochrobactrum anthropi*: dfrA14; *Parabacteroides distasonis*: cfxA2, ermF, tetX; *Pasteurella multocida*: sul2; *Peptoclostridium acidaminophilum*: tet32; *Phocaecicola coprophilus*: tetQ; *Porphyromonas cangingivalis*: cfxA2, ermF, mef(En2); *P. crevioricanis*: cfxA2, tetQ; *P. gingivalis*: cfxA2, mef(En2), pgpB; *Prevotella fusca*: tetQ; *P. intermedia*: ermF, mef(En2), tetQ, tetX; *Proteus vulgaris*: tet(H); *Providencia rettgeri*: aph(6)-Id, sul2; *Pseudomonas aeruginosa*: OXA-2, qacL, sul1; *P. putida*: tet(H); *Ralstonia insidiosa*: OXA-573; *R. pickettii*: OXA-22, OXA-60; *Riemerella anatipestifer*: aadS, ermF, OXA-347, tet(X4), tet(X5), tetX; *Roseburia intestinalis*: tet32; *Rothia nasimurium*: tet(Z); *Staphylococcus aureus*: aad(6), aph(3')-IIIa, SAT-4; *Streptococcus acidominimus*: tetO; *Streptococcus agalactiae*: aph(3')-IIIa, ermB; *S. anginosus*: tet32, tetO; *S. constellatus*: tet32, tetO; *S. equi*: lnuC, tet32, tetO; *S. gwangjuense*: lnuC; *S. parauberis*: tetS; *S. pluranimalium*: mel; *Streptococcus* sp. FDAARGOS_521: tetM; *S. suis*: ermB, lnuB, lsaE, tetO, tetW; *Tannerella forsythia*: cfxA2; *Trueperella pyogenes*: ermX; *Variovorax* sp. PAMC28562: aph(3'')-Ia; *Variovorax* sp. SRS16: aph(3'')-Ib, aph(6)-Id.

Based on the ARG content, the detected bacterial species may show resistance against the following antibiotic groups: *Acinetobacter baumannii*: aminoglycoside, carbapenem, cephalosporin, penam; *Actinobacillus pleuropneumoniae*: cephalosporin, penam; *Aeromonas hydrophila*: aminoglycoside, carbapenem, cephalosporin, penam, sulfonamide; *Alistipes indistinctus*: tetracycline; *A. shahii*: carbapenem, cephalosporin, lincosamide, macrolide, penam, streptogramin; *Amedibacterium intestinale*: aminoglycoside, tetracycline; *Bacteroides dorei*: tetracycline; *B. fragilis*: aminoglycoside, carbapenem, cephalosporin, glycylicycline, lincosamide, macrolide, penam, streptogramin, tetracycline; *B. heparinolyticus*: carbapenem, cephalosporin, penam, tetracycline; *B. ovatus*: tetracycline; *Bacteroides* sp. HF-5287: tetracycline; *Bibersteinia trehalosi*: cephalosporin, penam; *Blautia hansenii*: tetracycline; *Bulleidia* sp. zg-1006: tetracycline; *Capnocytophaga cynodegmi*: cephamycin; *Capnocytophaga* sp. H2931: aminoglycoside, carbapenem, cephalosporin, penam; *Capnocytophaga* sp. H4358: aminoglycoside, carbapenem, cephalosporin, penam; *C. stomatis*: aminoglycoside, carbapenem, cephalosporin, lincosamide, macrolide, penam, streptogramin, tetracycline; *Chryseobacterium indologenes*: aminoglycoside, lincosamide, macrolide, streptogramin; *Chryseobacterium* sp. POL2: carbapenem, cephalosporin, penam; *Clostridioides difficile*: aminoglycoside, lincosamide, macrolide, streptogramin, tetracycline; *Clostridium cellulovorans*: tetracycline; *Conchiformibius steedae*: cephalosporin, penam; *Corynebacterium* sp. 1959: aminoglycoside, sulfonamide; *Elizabethkingia anophelis*: carbapenem, cephalosporin, penam; *Empedobacter brevis*: carbapenem, cephalosporin, penam; *Enterocloster bolteae*: tetracycline; *E. faecalis*: tetracycline; *E. faecium*: aminoglycoside; *E. gilvus*: lincosamide, macrolide, streptogramin; *E. hirae*: tetracycline; *Enterococcus* sp. FDAARGOS_375: lincosamide, macrolide, streptogramin; *Escherichia coli*: acridine dye, aminoglycoside, cephalosporin, disinfecting agents and intercalating dyes, fluoroquinolone, glycylicycline, macrolide, monobactam, nucleoside, penam, penem, peptide, phenicol, rifamycin, tetracycline, triclosan; *Eubacterium maltosivorans*: tetracycline; *Eubacterium* sp. NSJ-61: tetracycline; *Faecalibacterium prausnitzii*: tetracycline; *Filifactor alocis*: tetracycline; *Fusobacterium ulcerans*: carbapenem, cephalosporin, penam; *Geobacter daltonii*: macrolide; *G. sulfurreducens*: carbapenem, cephalosporin, penam; *Glaesserella parasuis*: cephalosporin, penam; *Haemophilus haemolyticus*: cephalosporin, penam; *H. paraahaemolyticus*: aminoglycoside, sulfonamide; *Klebsiella michiganensis*: aminoglycoside, diaminopyrimidine, phenicol, sulfonamide; *K. quasipneumoniae*: aminoglycoside; *Lachnoanaerobaculum umeaense*: tetracycline; *Megasphaera stantonii*: tetracycline; *Mogibacterium pumilum*: tetracycline; *Moraxella bovis*: aminoglycoside, sulfonamide; *Murdochiella vaginalis*: tetracycline; *Myroides odoratimimus*: carbapenem, cephalosporin, penam; *Neisseria animaloris*: aminoglycoside; *N. shayegani*: aminoglycoside; *Ochrobactrum anthropi*: diaminopyrimidine; *Parabacteroides distasonis*: cephamycin, glycylicycline, lincosamide, macrolide, streptogramin, tetracycline; *Pasteurella multocida*: sulfonamide; *Peptoclostridium acidaminophilum*: tetracycline; *Phocaecicola coprophilus*: tetracycline; *Porphyromonas cangingivalis*: cephamycin, lincosamide, macrolide, streptogramin; *P. crevioricanis*: cephamycin, tetracycline; *P. gingivalis*: cephamycin, macrolide, peptide; *Prevotella fusca*: tetracycline; *P. intermedia*: glycylicycline, lincosamide, macrolide, streptogramin, tetracycline; *Proteus vulgaris*: tetracycline; *Providencia rettgeri*: aminoglycoside, sulfonamide; *Pseudomonas aeruginosa*: carbapenem, cephalosporin, disinfecting agents and intercalating dyes, penam, sulfonamide; *P. putida*: tetracycline; *Ralstonia insidiosa*: carbapenem, cephalosporin, penam; *R. pickettii*: carbapenem, cephalosporin, penam; *Riemerella anatipestifer*: aminoglycoside, carbapenem, cephalosporin, glycylicycline, lincosamide, macrolide, penam, streptogramin, tetracycline; *Roseburia intestinalis*: tetracycline; *Rothia nasimurium*: tetracycline; *Staphylococcus aureus*:

aminoglycoside, nucleoside; *Streptococcus acidominimus*: tetracycline; *S. agalactiae*: aminoglycoside, lincosamide, macrolide, streptogramin; *S. anginosus*: tetracycline; *S. constellatus*: tetracycline; *S. equi*: lincosamide, tetracycline; *S. gwangjuense*: lincosamide; *S. parauberis*: tetracycline; *S. pluranimalium*: lincosamide, macrolide, oxazolidinone, phenicol, pleuromutilin, streptogramin, tetracycline; *Streptococcus* sp. FDAARGOS_521: tetracycline; *S. suis*: lincosamide, macrolide, oxazolidinone, phenicol, pleuromutilin, streptogramin, tetracycline; *Tannerella forsythia*: cephamycin; *Trueperella pyogenes*: lincosamide, macrolide, streptogramin; *Variovorax* sp. PAMC28562: aminoglycoside; *Variovorax* sp. SRS16: aminoglycoside.

Mobilome

The frequencies of iMGEs, phages and plasmids associated with ARGs by bacteria of origin are summarized in Figure 3.




Figure 3. Mobile antimicrobial resistance gene frequency by bacteria of origin. The size of the dots indicates the occurrence frequency of the given gene flanked by iMGE, positioned in plasmid or phage.

Discussion

During the bacteriome, resistome and mobilome analysis of the canine saliva samples a large set of results was obtained that can be examined from a one health point of view, merging the small animal veterinary sector with the perspective of the human healthcare system.

A total of 35 bacterial genera were detected within the saliva samples, out of which several aerobic and anaerobic genera often get isolated from infected dog bite wounds. Dog bite infections are normally polymicrobial and the bite wound microbiota consists of bacteria from the animals' oral cavity, the recipients' skin and the environment. The most common pathogens in dog bites are *Pasteurella* spp. (*P. canis* and *P. multocida*), *Staphylococcus* spp., *Streptococcus* spp. and *Capnocytophaga* spp., *Porphyromonas* spp., *Bacteroides* spp., *Fusobacterium* spp. and *Corynebacterium* spp.³⁶ that all appeared in the analyzed saliva samples. Some other bacterial groups of a relatively higher clinical significance that were detected in the saliva samples including *Bacillus* spp., *Enterococcus* spp., *Moraxella* spp., *Neisseria* spp., *Prevotella* spp., *Pseudomonas* spp. are also often isolated from dog bite wound infections. The vast majority of other genera isolated in the samples have been mentioned to appear in dog saliva in previous publications with variable abundance rates^{13,37}. Even though some members of *Clostridium* spp. were detected in the samples, genome fragments of *C. tetani*, the bacterium responsible for tetanus were not identified.

The number of detected ARGs was relatively high in the salivary bacteriome. Examining 8 genera (*Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Capnocytophaga* spp., *Porphyromonas* spp., *Bacteroides* spp., *Fusobacterium* spp. and *Corynebacterium* spp.) that were indicated to be the most relevant ones in dog bite infections by other authors^{36,37} we could identify genes that confer resistance against aminoglycosides, carbapenems, cephalosporins, elfamycin, glycylicyclines, lincosamides, macrolides, oxazolidinone, penams, phenicols, pleuromutilins, streptogramins, sulfonamides, tetracyclines, while other antibiotic groups including fluoroquinolones appeared in the genome of bacteria with a relatively lower clinical relevance.

Such a great number and broad spectrum of ARGs and potentially affected antibiotic groups associated with the canine saliva samples may be related to the use of antibiotics at the small animal veterinary practice. Antibiotic consumption rates in companion animal sector are rather difficult to evaluate. However, some systems exist for the surveillance of magnitude of companion animal antibiotic consumption, such as European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)³⁸, VetCompass³⁹ or the Small Animal Veterinary Surveillance Network (SAVSNET)⁴⁰, these rates are still less well documented. Moreover, in many countries antimicrobial use is often just estimated of rough sales data²². Nevertheless, according to the two UK-based surveillance systems (VetCompass from Royal Veterinary College, and SAVSNET from Liverpool University) and one EU report (ESVAC) antibiotics are rather frequently prescribed at small animal clinics. A study states, 1 in 4 UK dogs (25.2%, 95% CI: 25.1–25.3%) was treated with antibiotics in a two-year period⁴¹. Even though, the vast majority of veterinarians are aware of the fact that improper AMU contributed to selection for antimicrobial resistance and that AMR is a significant problem according to nationwide surveys^{42,43}, there are many factors that influence the antibiotics prescription preferences of veterinarians besides the perspectives of antimicrobial stewardship. According to a study conducted in Australia, veterinarians often report client pressure to prescribe antibiotics as the most significant factor limiting antibiotic stewardship goals⁴⁴. In middle income countries, like South Africa cost may also influence the choice of antibiotics⁴⁵. In contrast, in studies conducted by other research groups from countries including the U.S.⁴⁶, the U.K.⁴⁷, the Netherlands⁴⁸ or Australia⁴⁹, clinical settings were ranked of a much higher importance than client expectations. Broad-spectrum amoxicillin-clavulanate is the flagship of antimicrobial agents applied in dogs in many countries, while first-generation cephalosporins are also routinely used^{22,50,51}. Lincosamides (clindamycin), macrolides, tetracyclines (doxycycline), nitroimidazoles and trimethoprim/sulphonamides have also been reported to be frequently used in small animal practice²². Third and fourth generation cephalosporins, fluoroquinolones and polymixins that belong to category B, 'last resort', or highest-priority Critically Important Antibiotics (HPCIA) according to the European Medicines Agency³⁸ should be avoided unless sensitivity testing is conducted, and no other antibiotics would be effective. Nevertheless, a HPCIA have been estimated to be prescribed in around 5-6% of total antibiotic usage events. Of the HPCIA category, fluoroquinolones are the most common in dogs, constituting ~4 to 5% of total antibiotic prescriptions⁵².

In the current literature, human infections associated to dog bites are better- and more frequently documented than the transmission route of licking. Three to 30% of dog bites leads to infection¹³. Management of animal bites rests on two pillars: local wound care and adequately applied systemic treatment. Essentials of local therapy include inspection, debridement of the wound accompanied by the removal of possible foreign bodies, e.g. teeth and irrigation with saline solution. Additional radiologic diagnostics should be performed to rule out fracture and if clinically indicated. Recommendations on primary or delayed closure of the wound and analyses on risk of appearance of consequent infections are controversial since studies show that at least 6-8% of mammalian bites will become infected after primary closure. On the other hand, according to one randomized trial, facial wounds for example, have a low risk of infection due to their excellent blood supply even after primary closure. without the use of prophylactic antibiotics^{53,54}. Wounds with delayed presentation and on the extremities should be left open⁵⁵. Culturing of fresh bite wounds without signs of an abscess, severe cellulitis or sepsis can be avoided⁵⁶. As for the systematic therapy, tetanus booster (if none given in past year) and rabies prophylaxis should always be considered. In

our study, genome fragments of *Clostridium tetani*, the causative agent of tetanus was not detected in any of the examined saliva samples. No consensus has yet been found in the use of antibiotics for animal bite wound care. Prophylactic antibiotics should be considered unless the wound is very superficial and clean. Explicit indications for antibiotic prophylaxis or therapy include presentation at least 8 hours after the bite, clear signs of superinfection, moderate or severe wounds with crush injuries or devitalized tissues requiring surgery, deep puncture wounds (exceeding the layer of epidermis), wounds close to joints, diabetes mellitus, asplenic or immunocompromised state, alcohol abuse, or involvement of the genital area, face or hand⁵⁶⁻⁶⁰. In the absence of the above reasons, antibiotic therapy may not be necessary. Interestingly, injuries are normally located on the head, neck and face by children and on the hand or upper extremity by adults due to height ratios with the attacking dog^{13,61}. The adequately chosen antibiotic agent is expected to be effective against anaerobe bacteria (*Bacteroides* spp., *Fusobacterium* spp., *Porphyromonas* spp., *Prevotella* spp. etc.), moreover *Staphylococcus*, *Streptococcus* and *Pasteurella* species. Prophylactic treatment is normally 3 to 5 days long, while medication for 10 days or longer is recommended if the wound is infected. The first-line choice for oral therapy is amoxicillin-clavulanate, accompanied with a first dose of intravenous antibiotic (e.g. ampicillinsulbactam, ticarcillin-clavulanate, piperacillin-tazobactam, or a carbapenem) in high risk patients. Amoxicillin-clavulanate is often combined with metronidazole or clindamycin, and is also sometimes replaced with cephalosporins, e.g. cefuroxime, cefotaxime, ceftriaxone, amoxicillin, fluoroquinolones, sulfamethoxazole and trimethoprim or, although less effective, azithromycin or doxycycline in this combination^{56,60}. Due to high resistance rates, flucloxacillin, erythromycin and cephalosporins are often ineffective in *Pasteurella* infections, thus should rather be avoided⁵⁸. In our case, no genes conferring resistance to these agent groups could be identified in *Pasteurella* spp.

Data on the outcome of antibiotic prophylaxis in animal bite management by humans is limited and rather controversial and conflicting. While a meta-analysis of 8 randomized trial indicated a benefit of antibiotic prophylaxis⁶², some studies concluded that antibiotic prophylaxis does not result in a statistically significant difference in the frequency of wound infections among treated and untreated patient groups, except for the wounds to the hand⁶³. Based on other publications, antibiotic prophylaxis should be recommended for the high-risk patient groups only^{64,65}.

Amoxicillin-clavulanate, the most commonly used antibiotic in small animal medicine and the first choice for canine bite wounds is a member of broad-spectrum penicillins, that has been a frequently consumed key antibiotic group in the high-income super-region between 2000 and 2018 by a global study⁶⁶. All in all, 23 ARG types were detected in the dog saliva samples that may confer resistance against amoxicillin-clavulanate, that were either the members of *blaTEM* or *OXA* family^{67,68}. *TEM-116* was identified in *E. coli*, while various members of the *OXA* family appeared in many genera, including *Acinetobacter baumannii*, *Bacteroides* spp., *Capnocytophaga* spp., *Corynebacterium* spp., *Fusobacterium ulcerans* and *Pseudomonas* spp. that can have a high clinical relevance in dog bite infections.

Many of the identified resistance genes harbored on iMGEs, phages or plasmids, with plasmids having the highest ARG association rates. Some genes could have been attached to two of the above mentioned mobility groups in the genome of one species, including the iMGE and phage co-appearance of aminoglycoside resistance encoding *aad(6)* and *aph(3')-IIIa* in *Enterococcus faecium*, the iMGE and plasmid co-appearance of *aph(3')-Ia* in *Corynebacterium* sp. 1959 and *Klebsiella quasipneumoniae*, *aph(3')-Ia* and *aph(6)-Id* in *Variovorax* sp. SRS16, *aph(3'')-Ib* in *Variovorax* sp. PAMC28562, tetracycline resistance encoding *tetM* in *Enterococcus faecalis*, phage and plasmid co-appearance of macrolide, lincosamide and streptogramin resistance encoding *ermB* in *Enterococcus* sp. FDAARGOS_375. *OXA-2*, *OXA-22*, *OXA-347* and *TEM-116*, genes associated with amoxicillin-clavulanate resistance all appeared in plasmids in various species, moreover *OXA-2* was associated with both an iMGE and a plasmid in the genome of *Pseudomonas aeruginosa*. The accumulation of various mobility factors around the genes may increase the chance of the horizontal transfer of the given ARG. The canine saliva-borne transmission of bacteria harboring mobile ARGs may hamper antibiotic use in human clinical settings and can also contribute to the spread of AMR among the bacteria deriving from pets to the bacteriota appearing in humans.

In the contrary, canine saliva had been used to promote rapid healing and to reduce bacterial contamination in the past according to reports of ethnoveterinary and ethnomedicinal practices^{69,70}. Antimicrobial and anti-inflammatory activity of canine saliva induced by thiocyanate, lysozyme and indirectly, nitrate, among others^{71,72} can even appear at low concentrations⁷³. However, according to our findings canine saliva can also be associated with public health risks, since salivary bacteria may contaminate the surroundings of people and may also colonize human skin and mucous membranes. Thus ARG-rich bacteria present in and around humans do not even necessarily need to transfer their ARGs, to potentially cause severe harm to various groups of people with weaknesses of the immune system, e.g. extremities in age or diseased state.

As a common trend among many nations, veterinary use of antibiotics is gradually declining^{38,44,52,74,75}. In human medicine, antibiotic sales elevated by 65% in low- and middle-income countries and decreased slightly, by 4% in high-income countries between 2000 and 2015, what adds up as a rise in global antibiotic consumption rates^{66,76}. As a presumable conclusion, several genes conferring resistance against clinically important antibiotic groups are present in the salivary bacteriome of dogs that may drift to the genome of bacteria in humans. Encounters with dog saliva and dog bites may serve as an interspecies

platform for the migration of bacteria and antimicrobial resistance genes. Transmitted bacteria may cause clinical symptoms and ARGs that they harbor may confer resistance against antibiotic agents of a clinical relevance.

Acknowledgements

The authors would like to thank the providers of BioProject PRJNA648123⁷⁷ and PRJNA683923. The research was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 874735 (VEO).

Author contributions statement

NS takes responsibility for the integrity of the data and the accuracy of the data analysis. AGT, LM and SN conceived the concept of the study. AGT, EGK and NS participated in the bioinformatic analysis. AGT, BR, EGK, IT and NS participated in the drafting of the manuscript. AD, AGT, ÁVP, BR, EGK, IT, LM, NS, SK and TN carried out the critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Additional information

Availability of data and material The datasets analysed in the current study are available in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) repository and can be accessed through the PRJNA648123⁷⁷ and PRJNA683923 BioProject identifiers.

Competing interests The authors declare that they have no competing interests.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

References

1. European Centre for Disease Prevention and Control (ECDC) , European Food Safety Authority (EFSA) & European Medicines Agency (EMA). Third joint inter-agency report on integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA. *EFSA J.* **19**, e06712, DOI: <https://doi.org/10.2903/j.efsa.2021.6712> (2021).
2. Manyi-Loh, C., Mamphweli, S., Meyer, E. & Okoh, A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. *Molecules* **23**, 795 (2018).
3. Tóth, A. G. *et al.* Antimicrobial resistance genes in raw milk for human consumption. *Sci. Rep.* **10**, 7464, DOI: [10.1038/s41598-020-63675-4](https://doi.org/10.1038/s41598-020-63675-4) (2020).
4. Rowan, A. N. Antibacterial prescribing patterns in small animal veterinary practice identified via savsnet: the small animal veterinary surveillance network. *Demogr. Stat. for Companion Animal Populations Collect.* **7**, 310–310 (2018).
5. Bedford, E. Number of dogs in the United States from 2000 to 2017. <https://www.statista.com/statistics/198100/dogs-in-the-united-states-since-2000> (2019). Accessed: 2022-03-06.
6. American Pet Products Association. 2021–2022 APPA National Pet Owners Survey. https://www.americanpetproducts.org/puBs_survey.asp (2022). Accessed: 2022-03-06.
7. Ho, J., Hussain, S. & Sparagano, O. Did the covid-19 pandemic spark a public interest in pet adoption? *Front. Vet. Sci.* **444** (2021).
8. Hoffman, C. L., Thibault, M. & Hong, J. Characterizing pet acquisition and retention during the covid-19 pandemic. *Front. veterinary science* **8** (2021).
9. Jensen, H. *AVMA Pet Ownership and Demographics Sourcebook* (American Veterinary Medical Association, 2017), 2017-2018 edn.
10. Overgaauw, P. A., Vinke, C. M., van Hagen, M. A. & Lipman, L. J. A one health perspective on the human–companion animal relationship with emphasis on zoonotic aspects. *Int. journal environmental research public health* **17**, 3789 (2020).
11. Gilchrist, J., Sacks, J. J., White, D. & Kresnow, M.-j. Dog bites: still a problem? *Inj. prevention* **14**, 296–301 (2008).
12. Loder, R. T. The demographics of dog bites in the united states. *Heliyon* **5**, e01360 (2019).
13. Dhillon, J., Hoopes, J. & Epp, T. Scoping decades of dog evidence: A scoping review of dog bite-related sequelae. *Can. J. Public Heal.* **110**, 364–375 (2019).

14. Overall, K. L. & Love, M. Dog bites to humans—demography, epidemiology, injury, and risk. *J. Am. Vet. Med. Assoc.* **218**, 1923–1934 (2001).
15. Shuler, C. M., DeBess, E. E., Lapidus, J. A. & Hedberg, K. Canine and human factors related to dog bite injuries. *J. Am. Vet. Med. Assoc.* **232**, 542–546 (2008).
16. Sánchez-Vizcaíno, F. *et al.* Demographics of dogs, cats, and rabbits attending veterinary practices in great britain as recorded in their electronic health records. *BMC veterinary research* **13**, 1–13 (2017).
17. Bir, C. *et al.* Familiarity and use of veterinary services by us resident dog and cat owners. *Animals* **10**, 483 (2020).
18. Guardabassi, L., Schwarz, S. & Lloyd, D. H. Pet animals as reservoirs of antimicrobial-resistant bacteria. *J. antimicrobial chemotherapy* **54**, 321–332 (2004).
19. Lloyd, D. H. Reservoirs of antimicrobial resistance in pet animals. *Clin. Infect. Dis.* **45**, S148–S152 (2007).
20. Pedersen, K. *et al.* Occurrence of antimicrobial resistance in bacteria from diagnostic samples from dogs. *J. Antimicrob. Chemother.* **60**, 775–781 (2007).
21. Damborg, P., Sørensen, A. H. & Guardabassi, L. Monitoring of antimicrobial resistance in healthy dogs: first report of canine ampicillin-resistant enterococcus faecium clonal complex 17. *Vet. microbiology* **132**, 190–196 (2008).
22. Pomba, C. *et al.* Public health risk of antimicrobial resistance transfer from companion animals. *J. Antimicrob. Chemother.* **72**, 957–968 (2017).
23. Goh, S. *Clostridium difficile: Methods and Protocols*, chap. Phage Transduction, 177–185 (Springer New York, 2016).
24. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome Biol.* **20**, 257, DOI: [10.1186/s13059-019-1891-0](https://doi.org/10.1186/s13059-019-1891-0) (2019).
25. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria (2021).
26. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. *PLoS One* **8**, e61217, DOI: [10.1371/journal.pone.0061217](https://doi.org/10.1371/journal.pone.0061217) (2013).
27. Lahti, L. & Shetty, S. microbiome R package (2012–2019).
28. Li, D., Liu, C.-M., Luo, R., Sadakane, K. & Lam, T.-W. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics* **31**, 1674–1676 (2015).
29. Hyatt, D. *et al.* Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinform.* **11**, 119, DOI: [10.1186/1471-2105-11-119](https://doi.org/10.1186/1471-2105-11-119) (2010).
30. McArthur, A. G. *et al.* The comprehensive antibiotic resistance database. *Antimicrob. Agents Chemother.* **57**, 3348–3357 (2013).
31. Jia, B. *et al.* CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic Acids Res.* **45**, D566–D573 (2017).
32. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. *Nat. Methods.* **12**, 59–60 (2015).
33. Johansson, M. H. *et al.* Detection of mobile genetic elements associated with antibiotic resistance in *Salmonella enterica* using a newly developed web tool: MobileElementFinder. *J. Antimicrob. Chemother.* **76**, 101–109 (2021).
34. Krawczyk, P. S., Lipinski, L. & Dziembowski, A. PlasFlow: predicting plasmid sequences in metagenomic data using genome signatures. *Nucleic Acids Res.* **46**, e35, DOI: [10.1093/nar/gkx1321](https://doi.org/10.1093/nar/gkx1321) (2018).
35. Guo, J. *et al.* VirSorter2: a multi-classifier, expert-guided approach to detect diverse DNA and RNA viruses. *Microbiome* **9**, 37, DOI: [10.1186/s40168-020-00990-y](https://doi.org/10.1186/s40168-020-00990-y) (2021).
36. Thomas, N. & Brook, I. Animal bite-associated infections: microbiology and treatment. *Expert. review anti-infective therapy* **9**, 215–226 (2011).
37. Abrahamian, F. M. & Goldstein, E. J. Microbiology of animal bite wound infections. *Clin. microbiology reviews* **24**, 231–246 (2011).
38. European Medicines Agency. European Surveillance of Veterinary Antimicrobial Consumption. Accessed: 2022-03-06.
39. McGreevy, P. *et al.* Vetcompass australia: a national big data collection system for veterinary science. *Animals* **7**, 74 (2017).

40. Radford, A. *et al.* Antibacterial prescribing patterns in small animal veterinary practice identified via savsnet: the small animal veterinary surveillance network. *Vet. Rec.* **169**, 310–310 (2011).
41. Buckland, E. L. *et al.* Characterisation of antimicrobial usage in cats and dogs attending uk primary care companion animal veterinary practices. *Vet. record* **179**, 489–489 (2016).
42. Odoi, A., Samuels, R., Carter, C. N. & Smith, J. Antibiotic prescription practices and opinions regarding antimicrobial resistance among veterinarians in kentucky, usa. *Plos one* **16**, e0249653 (2021).
43. Sobierajski, T., Mazińska, B., Chajęcka-Wierzchowska, W., Śmiałek, M. & Hryniewicz, W. Antimicrobial and antibiotic resistance from the perspective of polish veterinary students: An inter-university study. *Antibiotics* **11**, DOI: [10.3390/antibiotics11010115](https://doi.org/10.3390/antibiotics11010115) (2022).
44. Hardefeldt, L. Y. *et al.* Population wide assessment of antimicrobial use in dogs and cats using a novel data source—a cohort study using pet insurance data. *Vet. microbiology* **225**, 34–39 (2018).
45. Samuels, R., Qekwana, D. N., Oguttu, J. W. *et al.* Antibiotic prescription practices and attitudes towards the use of antimicrobials among veterinarians in the city of tshwane, south africa. *PeerJ* **9**, e10144 (2021).
46. Jacob, M. E. *et al.* Opinions of clinical veterinarians at a us veterinary teaching hospital regarding antimicrobial use and antimicrobial-resistant infections. *J. Am. Vet. Med. Assoc.* **247**, 938–944 (2015).
47. Hughes, L. A. *et al.* Cross-sectional survey of antimicrobial prescribing patterns in uk small animal veterinary practice. *Prev. Vet. Medicine* **104**, 309–316 (2012).
48. Hopman, N. E. *et al.* Attitudes and perceptions of dutch companion animal veterinarians towards antimicrobial use and antimicrobial resistance. *Prev. veterinary medicine* **170**, 104717 (2019).
49. Norris, J. M. *et al.* Factors influencing the behaviour and perceptions of australian veterinarians towards antibiotic use and antimicrobial resistance. *PLOS ONE* **14**, 1–19, DOI: [10.1371/journal.pone.0223534](https://doi.org/10.1371/journal.pone.0223534) (2019).
50. Kvaale, M., Grave, K., Kristoffersen, A. & Norström, M. The prescription rate of antibacterial agents in dogs in norway—geographical patterns and trends during the period 2004–2008. *J. veterinary pharmacology therapeutics* **36**, 285–291 (2013).
51. Tompson, A. C., Mateus, A. L., Brodbelt, D. C. & Chandler, C. I. Understanding antibiotic use in companion animals: A literature review identifying avenues for future efforts. *Front. veterinary science* **8** (2021).
52. Singleton, D. *et al.* Patterns of antimicrobial agent prescription in a sentinel population of canine and feline veterinary practices in the united kingdom. *The Vet. J.* **224**, 18–24 (2017).
53. Chen, E., Horing, S., Shepherd, S. M. & Hollander, J. E. Primary closure of mammalian bites. *Acad. Emerg. Medicine* **7**, 157–161 (2000).
54. Paschos, N. K., Makris, E. A., Gantsos, A. & Georgoulis, A. D. Primary closure versus non-closure of dog bite wounds. a randomised controlled trial. *Injury* **45**, 237–240 (2014).
55. Rui-feng, C., Li-song, H., Ji-bo, Z. & Li-qiu, W. Emergency treatment on facial laceration of dog bite wounds with immediate primary closure: a prospective randomized trial study. In *BMC emergency medicine*, vol. 13, 1–5 (Springer, 2013).
56. Aziz, H. *et al.* The current concepts in management of animal (dog, cat, snake, scorpion) and human bite wounds. *J. Trauma Acute Care Surg.* **78**, 641–648 (2015).
57. Ellis, R. & Ellis, C. Dog and cat bites. *Am. family physician* **90**, 239–243 (2014).
58. Malahias, M., Jordan, D., Hughes, O., Khan, W. S. & Hindocha, S. Bite injuries to the hand: microbiology, virology and management. *The open orthopaedics journal* **8**, 157–161, DOI: [10.2174/1874325001408010157](https://doi.org/10.2174/1874325001408010157) (2014).
59. Jakeman, M., Oxley, J. A., Owczarczak-Garstecka, S. C. & Westgarth, C. Pet dog bites in children: management and prevention. *BMJ paediatrics open* **4** (2020).
60. Zangari, A. *et al.* Dog bite injuries in a tertiary care children’s hospital: A seven-year review. *Pediatr. Int.* **63**, 575–580 (2021).
61. Monroy, A. *et al.* Head and neck dog bites in children. *Otolaryngol. – Head Neck Surg.* **140**, 354–357 (2009).
62. Cummings, P. Antibiotics to prevent infection in pateints with dog bite wounds: A meta-analysis of randomized trials. *Annals emergency medicine* **23**, 535–540 (1994).
63. Medeiros, I. M. & Saconato, H. Antibiotic prophylaxis for mammalian bites. *Cochrane Database Syst. Rev.* (2001).

64. Morgan, M. & Palmer, J. Dog bites. *Bmj* **334**, 413–7 (2007).
65. Stevens, D. L. *et al.* Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. *Clin. Infect. Dis.* **41**, 1373–1406, DOI: [10.1086/497143](https://doi.org/10.1086/497143) (2005). <https://academic.oup.com/cid/article-pdf/41/10/1373/34126296/41-10-1373.pdf>.
66. Browne, A. J. *et al.* Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. *The Lancet Planet. Heal.* **5**, e893–e904 (2021).
67. Di Conza, J. A. *et al.* β -lactamases produced by amoxicillin-clavulanate-resistant enterobacteria isolated in buenos aires, argentina: a new blatem gene. *Revista Argent. de microbiologia* **46**, 210–217 (2014).
68. Davies, T. J. *et al.* Reconciling the potentially irreconcilable? genotypic and phenotypic amoxicillin-clavulanate resistance in escherichia coli. *Antimicrob. agents chemotherapy* **64**, e02026–19 (2020).
69. Verrier, L. Dog licks man. *The Lancet* **295**, 615 (1970).
70. Vallejo, J. R., Santos-Fita, D. & González, J. A. The therapeutic use of the dog in spain: a review from a historical and cross-cultural perspective of a change in the human-dog relationship. *J. Ethnobiol. Ethnomedicine* **13**, 1–17 (2017).
71. Benjamin, N., Pattullo, S., Weller, R., Smith, L. & Ormerod, A. Wound licking and nitric oxide. *The Lancet* **349**, 1776 (1997).
72. Dhasarathan, P., Arunkumar, R., Blessy Jesubell, R. & Sowmya, P. Analysis of compounds and screening for anti-microbial, anti-inflammatory activity from saliva of canis lupus familiaris. *Int J Ethnomed Pharmacol Res* **1**, 1–6 (2013).
73. Akpomie, O., Ukoha, P., Nwafor, O. & Umukoro, G. Saliva of different dog breeds as antimicrobial agents against microorganisms isolated from wound infections. *Anim Sci J* **2**, 18–22 (2011).
74. Bager, F. *et al.* DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark (Statens Serum Institut, National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark, 2017).
75. Hopman, N. E. *et al.* Time trends, seasonal differences and determinants of systemic antimicrobial use in companion animal clinics (2012–2015). *Vet. microbiology* **235**, 289–294 (2019).
76. Sutherland, M. E. Antibiotic use across the globe. *Nat. Hum. Behav.* **2**, 373–373 (2018).
77. Ostrander, E. A. *et al.* Dog10k: an international sequencing effort to advance studies of canine domestication, phenotypes and health. *Natl. science review* **6**, 810–824 (2019).